boiling ethanol, refluxed for 10min and filtered. The residue was extracted twice with 200ml of hot ethanol and filtered, and the extracts were combined. After evaporation of the solution to neardryness, 250ml of water was added and the mixture was extracted three times with 50ml of diethyl ether. The ether extracts were dried over anhydrous Na2SO4 and the ether was removed by evaporation. The residue was dissolved in 3ml of chloroform and applied to a column (24cm long x 2.5 cm internal diam.) of silica gel (Kieselgel 60, from Merck, Darmstadt, W. Germany) equilibrated with chloroform. The column was developed with benzene/chloroform (1: 1, v/v), and 50ml fractions were collected after the elution firstly of a yellow fraction and secondly of a greeny-brown fraction. The progress of the elution was followed by t.l.c. on silica-gel sheets containing a bound fluorphor (Schleicher und Schiill, Dassel, W. Germany). The solvent was chloroform/propan-2-ol (19: 1, v/v). Spots were detected by short-wavelength u.v. light or staining with I2 vapour. Rotenoids were detected by their blue colour after spraying with HI reagent (Delfel, 1966) . Two rotenoids were found, the major one being eluted as a single spot in fractions 3-8 (RF 0.47) and co-migrating with authentic amorphigenin. These fractions were pooled and evaporated to dryness, and the residue was crystallized from benzene as white needles. The yield was 130mg, and n.m.r. and i.r. spectra of the product were identical with published spectra for amorphigenin (Claisse et al., 1964) . Synthesis of arylazido-f-alanine 4-Fluoro-3-nitrophenyl azide was synthesized as described by Fleet et al. (1972) from 4-fluoro-3-nitroaniline. Arylazido-p-alanine [3-amino-N-(4-azido-3-nitrophenyl) propanoic acid] was synthesized by the method of Guillory & Jeng (1977) from fl-alanine (1.07g) and 4-fluoro-3-nitrophenyl azide (1.8g). The yield was 1.33g (54%) and the compound appeared pure by t.l.c. on silica with water-saturated butan-l-ol and ethyl acetate/light petroleum (b.p. 40-60C)/acetic acid (25: 25: 1, by vol.) as solvents.
Synthesis of Alanine (32Ci/mmol) was obtained from Amersham International, Amersham, Bucks., U.K. Arylazido-#-[3H]alanine was synthesized from #-[3-3H]alanine (5mCi), f-alanine (22.3mg) and 4-fluoro-3-nitrophenyl azide (145mg) as described above. The yield was 18mg (29%) and the specific radioactivity was 2OCi/mol.
Synthesis of arylazidoamorphigenin
Arylazido-#-alanine (0.2mmol) and carbonyldiimidazole (0.22mmol) were dissolved in 4ml of dry tetrahydrofuran and allowed to react for 1h at room temperature under dry N2. Amorphigenin (0.2mmol) was added, followed by imidazolylsodium (0.2mmol in 0.3ml of tetrahydrofuran) made by dissolving Na in tetrahydrofuran containing excess imidazole. After 15 min at room temperature the reaction was stopped with 4ml of ice-cold 0.5M-HCI. The reaction mixture was extracted with chloroform, and the extracts were washed with NaHCO3 solution, water and then dried over anhydrous Na2SO4. T.l Weber & Osborn (1969) . Alternatively, samples were run on 12cm-long x 1.5 mm-thick slab gels containing a concave gradient of acrylamide between 13% (w/v) and 16% (w/v) (Earley & Ragan, 1981) . Gels were stained and destained by the method of Weber & Osborn (1969 Anti-(Complex I) serum was provided by M. W. J. Cleeter, of this department. Complex I was solubilized in Triton X-100 and immunoprecipitated as described by Heron et al. (1979) .
Results

Synthesis of arylazidoamorphigenin
Amorphigenin differs from rotenone by the presence of a hydroxy group in the substituent on the E ring ( Fig. 1 ). Modifications to this region of the rotenoid structure do not seem to affect inhibitory potency (F. G. P. Earley & C. I. Ragan, unpublished work) , and the hydroxy group provides a relatively straightforward means of synthesis of a photoaffinity analogue as shown in Scheme 1. Esterification of a hydroxy group by arylazido-,Balanine is the method used to synthesize photoaffinity analogues of NAD+ and NADP+ (e.g. Guillory & Jeng, 1977) . With use of the carbonyldi-imidazole alone, the esterification proceeded slowly and resulted in several reaction products. However, with imidazolylsodium present (Staab, 1962 ) the reaction proceeded rapidly to completion and only two products were formed, the major one of which was arylazidoamorphigenin.
The u.v.-visible-absorption spectrum of arylazidoamorphigenin is shown in Fig. 2(a) . Subtraction of the spectrum of arylazido-f-alanine to eliminate the 450nm peak resulted in a spectrum ( itself (Claisse et al., 1964) . Fig. 2(b) shows the spectroscopic changes resulting from photolysis of the compound.
Inhibitory properties ofarylazidoamorphigenin in the absence of light Arylazidoamorphigenin was a potent inhibitor of NADH-ubiquinone reductase activity of Complex I, comparable with rotenone or amorphigenin (see below). The extreme insolubility of the analogue may explain the slow kinetics of inhibition (Fig. 3) . inhibitor, non-specific binding also takes place, as is the case with rotenone (Horgan et al., 1968) . The extreme insolubility of the analogue makes this process all the more likely. Table 1 compares the protein labelling obtained with arylazidoamorphigenin and arylazido-p-alanine. Incorporation with the inhibitor was considerably higher, and moreover was much less sensitive to scavenging by reduced glutathione (Bayley & Knowles, 1980) . In addition, arylazido-f-alanine was not inhibitory at the concentrations used. Hatefi, 1979; Heron et al., 1979) . This leads to solubilization of 30% of the protein, including the FMN and most of the constituent iron-sulphur centres (Ragan et al., 1982a,b) . The solubilized material may be separated into two fractions, namely the flavoprotein fraction and the ironprotein fraction (Hatefi & Stempel, 1969; Ragan et al., 1982a,b) . The insoluble residue contains the more hydrophobic proteins and phospholipids and all the proteins that are in contact with the apolar region of the membrane (Earley & Ragan, 1980 , 1981 . When Complex I that had been treated in the dark with 1 mol of arylazidoamorphigenin/mol of enzyme was resolved with NaClO4, 74% of the radioactivity was recovered bound to protein. Of this, 83% was associated with the insoluble residue and only 9% and 8% was associated with the flavoprotein and iron-protein fractions respectively. This small labelling of the soluble material may have resulted either from non-specific binding of the inhibitor to the Complex I or from non-specific transfer of inhibitor during the resolution process. Gel electrophoresis of labelled Complex I Fig. 4 shows the distribution of radioactivity between Complex I polypeptides after photolabelling with arylazidoamorphigenin (1 nmol/mg of protein). Nearly all the radioactivity was associated with a major polypeptide, of Mr 33000. This protein is known to fractionate into the insoluble residue from NaClO4 resolution (Heron et al., 1979) . However, the recovery of radioactivity in this protein was only 4% of that added to the enzyme or 16% of that which was proteinbound after photolysis. The small amounts of radioactivity associated with other proteins cannot account for the discrepancy, and it is clear that the protein-bound radioactivity is unstable during electrophoresis. Staining and destaining of the gel had no effect on the incorporation of radioactivity into the 33000-Me protein, but the label was partially lost when the protein was dissolved in SDS and 2-mercaptoethanol. In one experiment, protein-bound radioactivity decreased by 30% after only 1 h at room temperature in 1% (w/v) SDS/1% (v/v) 2-mercaptoethanol. The radioactive profile was little affected by dissociating the sample at 20°C instead of 100°C, or by using Nethylmaleimide in place of 2-mercaptoethanol. Fig. 5 shows the incorporation achieved with higher concentrations of the photolabel (2nmol and 10nmol/mg of protein). Although labelling of the 33000-Mr polypeptide did not increase proportionally (i.e. it becomes saturated), labelling of other proteins can be seen, particularly at the highest concentration of analogue, where there is little specificity to the incorporation. Fig. 5 (Fig. 4) diminution of the intensity of this band can be brought about by dissociating the Complex I in SDS at 100°C rather than at 20°C. This causes aggregated protein to appear at the electrophoretic origin (Fig. 6 ), but did not lead to a decrease in the incorporation of arylazidoamorphigenin into the 33000-Mr polypeptide. Thus there are probably two different proteins that migrate to this position on gels, one of which can be aggregated by boiling, and the other of which is the site of labelling by the analogue. Even after 100°C treatment, though, the relative stain intensity of the band differs markedly in the two preparations.
Further evidence for this interpretation comes from Fig. 7 . The two Complex I preparations were incubated in Triton X-100 with antiserum to Complex I, and the immunoprecipitates were analysed by SDS/polyacrylamide-gel electrophoresis. As previously reported, the profiles are very similar to that of untreated Complex I except for the absence of a polypeptide of Mr 42000 The two preparations A (0) and B (A) were incubated with rotenone and assayed for NADHubiquinone reductase activity as described in the Materials and Methods section. Activity is expressed as the percentage of that which is inhibitable by 30nmol of rotenone/mg of protein (25mol/ mol of enzyme). (Smith & Ragan, 1980) . Treatment at 100°C no longer caused aggregated material to appear at the origin, and the intensity of the 33000Mr band was unaffected. We therefore conclude that the material that moves from this position to the origin on heating is an impurity. However, the relative stain intensity of the remaining band was still very different in the two preparations. Since The preparation with the higher concentration of the 33000 Mr protein could be labelled in this polypeptide by arylazidoamorphigenin to a much greater extent than the other (2-3-fold). Moreover, the two preparations also differed in their sensitivity to rotenone, as shown in Fig. 8 (Ragan & Heron, 1978) , and has also been encountered in rotenone inhibition of an NADHinduced semiquinone e.s.r. signal (Suzuki & King, 1983 ).
Discussion
We (Horgan et al., 1968) . Thirdly, we find that the 33000-Mr protein is present in Complex I from rat and rabbit tissue even though the overall polypeptide compositions of the enzyme in ox, rat and rabbit are appreciably different. This suggests a functional rather than a purely structural role for this protein. Fourthly, the variability of the content of this protein in different Complex I preparations correlates, not only with variation in the amount of label that can be incorporated, but also with the sensitivity of the enzyme to inhibition by rotenone.
The shapes of the rotenone inhibition curves of Fig. 8 could, in principle, be due to several causes. The possible dimeric nature of respiratory-chain complexes, including Complex I, has received considerable attention (e.g. Beinert & Albracht, 1982; De Vries et al., 1982) , and negative cooperativity between the monomers could explain the rotenone effect. Alternatively there may be two populations of Complex I molecules present that differ substantially in activity, presumably as a result of some alteration during the course of purification. If this alteration is, in fact, the loss of the 33000-Mr polypeptide, this could explain the variation in the rotenone titration curves, if we assume that activity through the deficient complexes is still rotenone-sensitive, but with decreased affinity for the inhibitor. This explanation fails to account for the observation that the initial activity of the two preparations of Fig. 8 was substantially the same, as was that of other preparations whose rotenone titration curves fell between the two examples given. Clearly it is essential to establish whether or not the rotenone inhibition curve is a preparation artifact, and to correlate inhibition with rotenone binding rather than the concentration of rotenone added. In this context, it is known that there is only one class of specific piericidin-binding sites on Complex I ; nevertheless, the variation in sensitivity to rotenone shown in Fig. 8 is paralleled by a similar variation in sensitivity to piericidin (F. G. P. Earley & C. I. Ragan, unpublished work) . The low specific radioactivity of the analogue and its poor incorporation into protein made it impossible to confirm our results with intact mitochondria and submitochondrial particles. Further work should be directed towards the synthesis of alternative photoaffinity-labelling analogues of both rotenone and piericidin to help resolve some of the peculiarities uncovered by the work described here.
